Fenster schließen  |  Fenster drucken

[posting]43511128[/posting]PR von SQNM von 13:00

LifeCodexx Launches PraenaTest in Germany, Austria, Liechtenstein and Switzerland With Sequenom-Licensed Technology

SAN DIEGO, Aug. 20, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced that its European licensing partner, LifeCodexx, is launching its PraenaTest service in more than 70 prenatal clinics and hospitals in Germany, Austria, Liechtenstein and Switzerland. This follows receipt of a CE Mark, a regulatory approval allowing LifeCodexx to market the test.

"Based on our licensing agreement with Sequenom, we are pleased to be the first to provide such a testing service in the German speaking countries," said Dr. Michael Lutz, CEO of LifeCodexx AG. "The PraenaTest fulfills the clinical requirement of physicians and patients as a safer method to assess the risk of a pregnancy carrying fetal trisomy 21."

The highly accurate non-invasive genetic blood test is intended for use among women whose pregnancies are at increased risk for fetal aneuploidy, specifically to detect fetal trisomy 21. It is a complement to other prenatal assessments and can help determine whether invasive diagnostic testing, such as amniocentesis, is necessary.

"We're very proud to see an international acceptance of our proprietary cell-free DNA technology through our successful collaboration with LifeCodexx," said Harry S. Hixson, Jr., Ph.D., Chairman and CEO of Sequenom. "We are pleased to see LifeCodexx providing the PraenaTest for women who are at increased risk of carrying a child with trisomy 21."

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.
aus der Diskussion: SQNM Trisomie Test ab heute über Lifecodexx Praenatest in D AT CH LI
Autor (Datum des Eintrages): medisana  (20.08.12 13:03:38)
Beitrag: 2 von 2 (ID:43511602)
Alle Angaben ohne Gewähr © wallstreet:online